Skip to main content

Definitive Healthcare launches Latitude Discovery for pre-commercial biopharma and medical device companies

Written by Customer Service on . Posted in Public Companies.

By iteratively analyzing and reporting on real-world data, life sciences organizations can quickly assess multiple market opportunities during therapy development

FRAMINGHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the availability of Latitude Discovery, a new product aimed at pre-commercial biopharma and medical device companies. With Latitude Discovery, users can quickly perform iterative analysis of real-world data to assess and size potential market opportunities associated with therapy development for granular patient cohorts.

Latitude Discovery is purposefully designed to meet the needs of pre-commercial pharmaceutical, biotechnology and medical device companies who are looking to bring new treatments to market. With billions of commercial medical claims, Latitude Discovery users gain self-service access to the precise market intelligence they need when they need it as they advance through the lengthy commercialization process.

Key capabilities of Latitude Discovery include:

  • The ability to quickly create new patient cohorts for analysis and reporting using any combination of diagnosis or procedure with additional filters on patients and providers
  • Rapid real-time commercial intelligence visualizations on the size of addressable patient and provider populations, clinical volumes, demographics and payor mix
  • Customizable claims data report templates to understand all additional diagnoses and procedures associated with the target population

“Bringing a new treatment to market is an incredibly lengthy and arduous process that requires years of work, hefty investments of time and money, and clearing many regulatory hurdles,” said Jason Krantz, CEO and founder of Definitive Healthcare. “With Latitude Discovery, companies at the very beginning of this journey now have a solution tailored to them. From discovery and development to full commercial activation, Definitive Healthcare delivers the healthcare commercial intelligence that life sciences organizations need at every step.”

Latitude Discovery is part of the Latitude Analytics Suite, a new reporting and analytics package that enables companies of all sizes to accelerate their commercialization efforts with real-time analytics leveraging Definitive Healthcare data and intelligence. The first product in the suite, Latitude Reporting, targets life sciences companies in the commercial phase and was released in October 2021.

Request a demo of Latitude Discovery at definitivehc.com/free-trial.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Media Contact:

Danielle Johns
djohns@definitivehc.com

Highwire PR

definitivehealthcare@highwirepr.com

Investor Relations Contact:

Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.